TY - JOUR AU - Brückner, Edit AU - Bedics, Gábor AU - Reiniger, Lilla AU - Rajnai, Hajnalka AU - Jakab, Zsuzsanna AU - Bödör, Csaba AU - Scheich, Bálint AU - Garami, Miklós TI - Gyermekkori agydaganatok: diagnózis és terápia – komprehenzív genomikai profilozás JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 67 PY - 2023 IS - 4 SP - 315 EP - 320 PG - 6 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34444932 ID - 34444932 AB - With the advancement of molecular oncology, numerous new opportunities are available for the effective and efficient treatment of patients diagnosed with childhood brain tumors. This includes gene panel analysis aiding personalized treatment used in clinical trials, and the application of targeted therapy independent of tissue type (tumor agnostic therapy). Most personalized therapies inhibit certain kinases. In our review, we present the modern pathological diagnosis of childhood brain tumors, as well as the complex intracellular regulation of signal transduction pathways important from the point of view of clinical practice, and we describe their further targets defined on the basis of pharmacological characteristics of the pathway, based on international and our own results. Despite common mutations affecting kinases, personalized therapy is not available in many types of tumors. Through the example of childhood brain tumors, we demonstrate the expected future therapeutic significance of tyrosine kinases. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Bedics, Gábor AU - Szőke, P. AU - Bátai, Bence AU - Nagy, Tibor AU - Papp, Gergő AU - Kránitz, N. AU - Rajnai, Hajnalka AU - Reiniger, Lilla AU - Bödör, Csaba AU - Scheich, Bálint TI - Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-023-45786-w UR - https://m2.mtmt.hu/api/publication/34258190 ID - 34258190 N1 - Funding Agency and Grant Number: Semmelweis University; EU's Horizon 2020 Research and Innovation Program [739593]; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund [TKP2021-EGA-24, TKP2021-NVA-11]; UNKP-22-3-II New National Excellence Program of the Ministry for Culture and Innovation from the National Research, Development and Innovation Fund Funding text: Open access funding provided by Semmelweis University. This work was funded by the EU's Horizon 2020 Research and Innovation Program under grant agreement No. 739593, by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-24 and TKP2021-NVA-11 funding schemes as well as the UNKP-22-3-II New National Excellence Program of the Ministry for Culture and Innovation from the National Research, Development and Innovation Fund. LA - English DB - MTMT ER - TY - JOUR AU - Gyulai, Márton AU - Megyesfalvi, Zsolt AU - Reiniger, Lilla AU - Harko, Tunde AU - Ferencz, Bence AU - Karsko, Luca AU - Agócs, László AU - Fillinger, Janos AU - Döme, Balázs AU - Szállási, Zoltán AU - Moldvay, Judit TI - PD-1 and PD-L1 expression in rare lung tumors JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 29 PY - 2023 PG - 9 SN - 1219-4956 DO - 10.3389/pore.2023.1611164 UR - https://m2.mtmt.hu/api/publication/33999222 ID - 33999222 N1 - Funding Agency and Grant Number: Ministry for Innovation and Technology of Hungary; Hungarian Respiratory Society [UNKP-20-3, UNKP-21-3]; IASLC/ILCF Young Investigator Grant [2020]; Semmelweis 250+ Excellence PhD Scholarship by Semmelweis University; Hungarian National Research, Development and Innovation Office [EFOP-3.6.3-VEKOP-16-2017-00009]; Austrian Science Fund [KH130356, K129065, KNN121510]; Breast Cancer Research Foundation [FWF I3977, I4677]; Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant; Hungarian National Research, Development and Innovation Office [NNF15OC0016584]; Hungarian Brain research Program [K129065]; [2017-1.2.1-NKP-2017-00002] Funding text: ZM was supported by the UNKP-20-3 and UNKP-21-3 New National Excellence Program of the Ministry for Innovation and Technology of Hungary and by the Hungarian Respiratory Society (MPA #2020). ZM is also the recipient of the IASLC/ILCF Young Investigator Grant. BF is a recipient of Semmelweis 250+ Excellence PhD Scholarship (EFOP-3.6.3-VEKOP-16-2017-00009) by Semmelweis University. BD acknowledge funding from the Hungarian National Research, Development and Innovation Office (KH130356, K129065, and KNN121510) and the Austrian Science Fund (FWF I3977 and I4677). ZS was supported by the Breast Cancer Research Foundation and the Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant (NNF15OC0016584). JM was supported by the Hungarian National Research, Development and Innovation Office (K129065) and by the Hungarian Brain research Program (grant 2017-1.2.1-NKP-2017-00002). AB - Background: Our knowledge is still limited about the characteristics and treatment of rare lung tumors. The aim of our study was to determine programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) expression in rare pulmonary tumors to assess the potential role of immunotherapy. LA - English DB - MTMT ER - TY - JOUR AU - Woldmar, N AU - Schwendenwein, A AU - Kuras, M AU - Szeitz, Beáta AU - Boettiger, K AU - Sólyom-Tisza, Anna AU - Laszlo, Viktoria AU - Reiniger, Lilla AU - Bagó, Attila György AU - Szállási, Zoltán AU - Moldvay, Judit AU - Szász, Attila Marcell AU - Malm, J AU - Horvatovich, P AU - Pizzatti, L AU - Domont, G B AU - Rényi-Vámos, Ferenc István AU - Hoetzenecker, K AU - Hoda, M A AU - Marko-Varga, G AU - Schelch, K AU - Megyesfalvi, Zsolt AU - Rezeli, M AU - Döme, Balázs TI - Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases JF - ESMO OPEN J2 - ESMO OPEN VL - 8 PY - 2023 IS - 1 PG - 13 SN - 2059-7029 DO - 10.1016/j.esmoop.2022.100741 UR - https://m2.mtmt.hu/api/publication/33364842 ID - 33364842 AB - Background Brain metastases are associated with considerable negative effects on patients’ outcome in lung adenocarcinoma (LADC). Here, we investigated the proteomic landscape of primary LADCs and their corresponding brain metastases. Materials and methods Proteomic profiling was conducted on 20 surgically resected primary and brain metastatic LADC samples via label-free shotgun proteomics. After sample processing, peptides were analyzed using an Ultimate 3000 pump coupled to a QExactive HF-X mass spectrometer. Raw data were searched using PD 2.4. Further data analyses were carried out using Perseus, RStudio and GraphPad Prism. Proteomic data were correlated with clinical and histopathological parameters and the timing of brain metastases. Mass spectrometry-based proteomic data are available via ProteomeXchange with identifier PXD027259. Results Out of the 6821 proteins identified and quantified, 1496 proteins were differentially expressed between primary LADCs and corresponding brain metastases. Pathways associated with the immune system, cell-cell/matrix interactions and migration were predominantly activated in the primary tumors, whereas pathways related to metabolism, translation or vesicle formation were overrepresented in the metastatic tumors. When comparing fast- versus slow-progressing patients, we found 454 and 298 differentially expressed proteins in the primary tumors and brain metastases, respectively. Metabolic reprogramming and ribosomal activity were prominently up-regulated in the fast-progressing patients (versus slow-progressing individuals), whereas expression of cell-cell interaction- and immune system-related pathways was reduced in these patients and in those with multiple brain metastases. Conclusions This is the first comprehensive proteomic analysis of paired primary tumors and brain metastases of LADC patients. Our data suggest a malfunction of cellular attachment and an increase in ribosomal activity in LADC tissue, promoting brain metastasis. The current study provides insights into the biology of LADC brain metastases and, moreover, might contribute to the development of personalized follow-up strategies in LADC. LA - English DB - MTMT ER - TY - JOUR AU - Bedics, Gábor AU - Csóka, Monika AU - Reiniger, Lilla AU - Varga, Edit AU - Liptai, Zoltán AU - Papp, Gergő AU - Bekő, Anna AU - Cervi, Catherine AU - Bödör, Csaba AU - Scheich, Bálint TI - Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement JF - ACTA NEUROPATHOLOGICA J2 - ACTA NEUROPATHOL VL - 145 PY - 2023 IS - 1 SP - 153 EP - 156 PG - 4 SN - 0001-6322 DO - 10.1007/s00401-022-02520-6 UR - https://m2.mtmt.hu/api/publication/33283318 ID - 33283318 N1 - Correspondence LA - English DB - MTMT ER - TY - JOUR AU - Bedics, Gábor AU - Kotmayer, Lili AU - Zajta, Erik AU - Hegyi, Lajos László AU - Brückner, Edit AU - Rajnai, Hajnalka AU - Reiniger, Lilla AU - Bödör, Csaba AU - Garami, Miklós AU - Scheich, Bálint TI - Germline MUTYH mutations and high-grade gliomas: Novel evidence for a potential association JF - GENES CHROMOSOMES & CANCER J2 - GENE CHROMOSOME CANC VL - 61 PY - 2022 IS - 10 SP - 622 EP - 628 PG - 7 SN - 1045-2257 DO - 10.1002/gcc.23054 UR - https://m2.mtmt.hu/api/publication/32827525 ID - 32827525 N1 - Funding Agency and Grant Number: Nemzeti Kutatasi, Fejlesztesi es Innovacios Alap; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund [UNKP-21-2-I-SE-21-KL, EFOP-3.6.3-VEKOP-16-2017-00009, TKP2021-NVA-11, TKP2021-EGA-24]; U's Horizon 2020 Research and Innovation Program [739593] Funding text: Nemzeti Kutatasi, Fejlesztesi es Innovacios Alap; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, Grant/Award Numbers: UNKP-21-2-I-SE-21-KL, EFOP-3.6.3-VEKOP-16-2017-00009, TKP2021-NVA-11, TKP2021-EGA-24; EU's Horizon 2020 Research and Innovation Program, Grant/Award Number: 739593 LA - English DB - MTMT ER - TY - JOUR AU - Veres, T. AU - Voniatis, Constantinos AU - Molnár, Kristóf AU - Nesztor, D. AU - Fehér, Daniella AU - Ferencz, Andrea AU - Gresits, Iván AU - Thuróczy, G. AU - Márkus, Bence Gábor AU - Simon, Ferenc AU - Nemes, N.M. AU - García-Hernández, M. AU - Reiniger, Lilla AU - Horváth, I. AU - Máthé, Domokos AU - Szigeti, Krisztián AU - Csákiné Tombácz, Etelka AU - Jedlovszky-Hajdú, Angéla TI - An Implantable Magneto-Responsive Poly(aspartamide) Based Electrospun Scaffold for Hyperthermia Treatment JF - NANOMATERIALS J2 - NANOMATERIALS-BASEL VL - 12 PY - 2022 IS - 9 PG - 15 SN - 2079-4991 DO - 10.3390/nano12091476 UR - https://m2.mtmt.hu/api/publication/32816292 ID - 32816292 AB - When exposed to an alternating magnetic field, superparamagnetic nanoparticles can elicit the required hyperthermic effect while also being excellent magnetic resonance imaging (MRI) contrast agents. Their main drawback is that they diffuse out of the area of interest in one or two days, thus preventing a continuous application during the typical several-cycle multi-week treatment. To solve this issue, our aim was to synthesise an implantable, biodegradable membrane infused with magnetite that enabled long-term treatment while having adequate MRI contrast and hyperthermic capabilities. To immobilise the nanoparticles inside the scaffold, they were synthesised inside hydrogel fibres. First, polysuccinimide (PSI) fibres were produced by electrospinning and crosslinked, and then, magnetitc iron oxide nanoparticles (MIONs) were synthesised inside and in-between the fibres of the hydrogel membranes with the well-known co-precipitation method. The attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) investigation proved the success of the chemical synthesis and the presence of iron oxide, and the superconducting quantum interference device (SQUID) study revealed their superparamagnetic property. The magnetic hyperthermia efficiency of the samples was significant. The given alternating current (AC) magnetic field could induce a temperature rise of 5 degrees C (from 37 degrees C to 42 degrees C) in less than 2 min even for five quick heat-cool cycles or for five consecutive days without considerable heat generation loss in the samples. Short-term (1 day and 7 day) biocompatibility, biodegradability and MRI contrast capability were investigated in vivo on Wistar rats. The results showed excellent MRI contrast and minimal acute inflammation. LA - English DB - MTMT ER - TY - JOUR AU - Sebestyén, Endre AU - Nagy, Ákos AU - Marosvári, Dóra AU - Rajnai, Hajnalka AU - Kajtár, Béla AU - Deák, Beáta AU - Matolcsy, András AU - Brandner, Sebastian AU - Storhoff, James AU - Chen, Ning AU - Bagó, Attila György AU - Bödör, Csaba AU - Reiniger, Lilla TI - Distinct miRNA expression signatures of primary and secondary central nervous system lymphomas JF - JOURNAL OF MOLECULAR DIAGNOSTICS J2 - J MOL DIAGN VL - 24 PY - 2022 IS - 3 SP - 224 EP - 240 PG - 17 SN - 1525-1578 DO - 10.1016/j.jmoldx.2021.11.005 UR - https://m2.mtmt.hu/api/publication/32551575 ID - 32551575 N1 - Funding Agency and Grant Number: Hungarian Science Foundation [OTKA-PD115792]; Hungarian National Research, Development and Innovation Office [KH17-126718, K21-137948, TKP2021-EGA-24, FK-132666]; European Union [739593]; Hungarian Brain Research Program [2017-1.2.1-NKP-2017-00002]; Semmelweis University Science and Innovation Fund [STIA_18_KF, STIA_21_KF]; Elixir Hungary [KA-2019-32]; Co-operative Doctoral Program of the Ministry of Inno-vation and Technology; National Research, Developmentand Innovation Fund; National Institute for Health Research Biomedical Research Center's funding scheme to Uni-versity College London Hospitals [BRC399/NS/RB/101410]; Medical Research Council BRAIN UK [MR/N004272/1]; Brain Tumor Research Funding text: Supported by the Hungarian Science Foundation OTKA-PD115792 (L.R.) , Hungarian National Research, Development and Innovation Office KH17-126718, K21-137948, and TKP2021-EGA-24 (C.B.) and FK-132666 (E.S.) , and the European Union's Horizon 2020 research and innovation program under grant agreement 739593 (C.B.) . Furthermore, the study was supported by the Hungarian Brain Research Program 2017-1.2.1-NKP-2017-00002 (L.R.) , Semmelweis University Science and Innovation Fund STIA_18_KF (E.S.) and STIA_21_KF (C.B.) , Elixir Hungary (C.B.) , the research grant of the University of Pecs Medical School KA-2019-32 (B.K.) , and the Co-operative Doctoral Program of the Ministry of Inno-vation and Technology, financed from the National Research, Developmentand Innovation Fund (a.N.) . Supported in part by the National Institute for Health Research Biomedical Research Center's funding scheme to Uni-versity College London Hospitals BRC399/NS/RB/101410 (S.B.) . The UK Brain Archive Information Network (BRAIN UK) is funded by the Medical Research Council BRAIN UK MR/N004272/1 and Brain Tumor Research. AB - Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma that might arise in the CNS (primary CNS lymphoma, PCNSL) or disseminates from a systemic lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Dysregulated expression of microRNAs (miRNAs) is associated with various pathological processes and miRNA expression patterns may have diagnostic, prognostic and therapeutic implications. However, miRNA expression is understudied in CNS lymphomas. We performed expression analysis of 798 miRNAs in 73 CNS lymphoma samples using the NanoString platform, followed by an analysis to identify potential diagnostic biomarkers characterizing subgroups and to examine differences based on their primary and secondary nature, molecular subtype, mutational patterns and survival. We identified 31 differentially expressed miRNAs between primary and secondary groups. Additionally, we identified 7 more miRNAs associated with a molecular subtype and 25 associated with mutation status. Using unsupervised clustering methods, we defined a small but distinct primary CNS lymphoma subgroup, with characteristically different expression patterns compared to the rest of the cases. Finally, we identified differentially regulated pathways in the above comparisons and assessed the utility of miRNA expression patterns in predicting survival. Our study identifies a novel CNS lymphoma subgroup defined by distinct miRNAs, proves the importance of specific miRNAs and pathways in their pathogenesis, and provides the basis for future research in defining potential biomarkers. LA - English DB - MTMT ER - TY - JOUR AU - Jósa, Valéria AU - Féderer, Krisztina AU - Zrubka, Zsombor AU - Reiniger, Lilla AU - Baranyai, Zsolt TI - Az interleukin-6-expresszió vizsgálata colorectalis adenocarcinomában szenvedő betegeken JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - 37 SP - 1502 EP - 1507 PG - 6 SN - 0030-6002 DO - 10.1556/650.2021.32206 UR - https://m2.mtmt.hu/api/publication/32304658 ID - 32304658 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Molnár, Kristóf AU - Voniatis, Constantinos AU - Fehér, Daniella AU - Szabó, Györgyi AU - Pázmány, Rita AU - Reiniger, Lilla AU - Juriga, Dávid AU - Kiss, Zoltan AU - Molnárné Krisch, Enikő AU - Wéber, György AU - Ferencz, Andrea AU - Varga, Gábor AU - Zrínyi, Miklós AU - S. Nagy, Krisztina AU - Jedlovszky-Hajdú, Angéla TI - Poly(amino acid) based fibrous membranes with tuneable in vivo biodegradation JF - PLOS ONE J2 - PLOS ONE VL - 16 PY - 2021 IS - 8 PG - 21 SN - 1932-6203 DO - 10.1371/journal.pone.0254843 UR - https://m2.mtmt.hu/api/publication/32153027 ID - 32153027 N1 - Laboratory of Nanochemistry, Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary Department of Food, Agricultural and Biological Engineering, College of Food, Agricultural, and Environmental Sciences, The Ohio State University, Wooster, OH, United States Department of Surgical Research and Techniques, Semmelweis University, Budapest, Hungary 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary Department of Polymer Engineering, Faculty of Mechanical Engineering, Budapest University of Technology and Economics, Budapest, Hungary Biomechanical Research Center, Faculty of Mechanical Engineering, Budapest University of Technology and Economics, Budapest, Hungary Department of Oral Biology, Semmelweis University, Budapest, Hungary Cited By :1 Export Date: 5 April 2022 CODEN: POLNC Correspondence Address: Jedlovszky-Hajdu, A.; Laboratory of Nanochemistry, Hungary; email: hajdu.angela@med.semmelweis-univ.hu Chemicals/CAS: disulfide, 16734-12-6; amino acid, 65072-01-7; Amino Acids; Biocompatible Materials; Membranes, Artificial Funding details: Semmelweis Egyetem, EFOP-3.6.3-VEKOP-16-2017-00009 Funding details: Magyar Tudományos Akadémia, MTA Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, FK 124147 Funding details: Innovációs és Technológiai Minisztérium, NKP-20-5-SE-9 Funding details: National Research, Development and Innovation Office Funding text 1: This work was supported by the National Research, Development and Innovation Office (NKFIH FK 124147), the J?nos Bolyai Research Scholarship of the Hungarian Academy of Sciences (JHA) and by the new national excellence program of the Ministry for Innovation and Technology (?NKP-20-5-SE-9). The research was further financed by the Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary, within the framework of the Therapeutic Development thematic programme of the Semmelweis University and by EFOP-3.6.3-VEKOP-16-2017-00009. LA - English DB - MTMT ER -